Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.2 USD -29.34% Intraday chart for Avenue Therapeutics, Inc. -36.41% -48.65%
Mar. 18 Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 22 Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 159.9 99.64 5.544 2.133 3.659 - -
Enterprise Value (EV) 1 159.9 99.64 5.544 2.133 3.659 3.659 3.659
P/E ratio -5.82 x -19.2 x -0.71 x -0.16 x -0.2 x -0.22 x -0.19 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - - - - - - -
EV / FCF - - - -0.14 x -0.27 x -0.24 x -0.18 x
FCF Yield - - - -695% -364% -424% -551%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 14.8 14.9 63.7 177 590.1 - -
Reference price 2 10,800 6,694 87.00 12.08 6.200 6.200 6.200
Announcement Date 3/30/20 3/31/21 3/30/23 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net sales 1 - - - - - - -
EBITDA - - - - - - -
EBIT 1 -26.26 -5.213 -8.043 -14.54 -13.31 -15.5 -19.92
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 -25.91 -5.151 - -10.49 -13.31 -15.5 -19.92
Net income 1 -25.91 -5.151 -3.552 -10.38 -13.31 -15.5 -19.92
Net margin - - - - - - -
EPS 2 -1,856 -348.8 -122.3 -73.50 -30.75 -27.75 -33.00
Free Cash Flow 1 - - - -14.83 -13.31 -15.5 -20.17
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/30/20 3/31/21 3/30/23 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - -
EBIT 1 -0.872 - -3.912 -6.429 -3.923 -2.068 -2.119 -3.061 -3.194 -3.46 -3.594
Operating Margin - - - - - - - - - - -
Earnings before Tax (EBT) 1 -0.871 - - - - - 0.617 -3.061 -3.194 -3.46 -3.594
Net income 1 -0.871 -0.662 0.575 -7.536 -4.007 0.526 0.64 -3.061 -3.194 -3.46 -3.594
Net margin - - - - - - - - - - -
EPS 2 -56.25 -33.75 92.25 -102.8 -39.00 4.500 42.00 -9.000 -7.500 -8.250 -6.750
Dividend per Share - - - - - - - - - - -
Announcement Date 11/15/21 11/10/22 3/30/23 5/10/23 8/10/23 11/13/23 3/18/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - -14.8 -13.3 -15.5 -20.2
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/30/20 3/31/21 3/30/23 3/18/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.2 USD
Average target price
1,228 USD
Spread / Average Target
+19,708.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AVENUE THERAPEUTICS, INC. Stock Avenue Therapeutics, Inc.
-48.65% 3.66M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. Financials Avenue Therapeutics, Inc.